Abstract |
Drug resistance frequently results in poor prognosis and high 5-year recurrence rate in estrogen receptor-negative (ER-) breast cancer patients. Herein, we examined the reversal effects of fulvestrant on multidrug resistance (MDR) in ER- breast cancer cells. Co-administration of fulvestrant significantly sensitized ER- MDR tumors to paclitaxel both in vitro and in vivo. Further analyses indicated that fulvestrant did not affect P-gp expression, but could inhibit P-gp function and subsequently reverse P-gp mediated drug resistance in ER- breast cancer cells. These results showed that combination of fulvestrant and chemotherapeutic agents might provide an effective treatment for ER- MDR breast cancers.
|
Authors | Donghai Jiang, Yuan Huang, Ning Han, Mingjie Xu, Liang Xu, Lin Zhou, Shu Wang, Weimin Fan |
Journal | Cancer letters
(Cancer Lett)
Vol. 346
Issue 2
Pg. 292-9
(May 01 2014)
ISSN: 1872-7980 [Electronic] Ireland |
PMID | 24462822
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- ATP Binding Cassette Transporter, Subfamily B, Member 1
- Antineoplastic Agents, Hormonal
- Estrogen Receptor Modulators
- Receptors, Estrogen
- Fulvestrant
- Estradiol
- Paclitaxel
|
Topics |
- ATP Binding Cassette Transporter, Subfamily B, Member 1
(antagonists & inhibitors, metabolism)
- Animals
- Antineoplastic Agents, Hormonal
(pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Apoptosis
(drug effects)
- Breast Neoplasms
(drug therapy, metabolism, pathology)
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Drug Synergism
- Estradiol
(administration & dosage, analogs & derivatives, pharmacology)
- Estrogen Receptor Modulators
(pharmacology)
- Female
- Fulvestrant
- Humans
- Mice
- Mice, Nude
- Mitosis
(drug effects)
- Paclitaxel
(administration & dosage, pharmacology)
- Random Allocation
- Receptors, Estrogen
(deficiency, metabolism)
- Xenograft Model Antitumor Assays
|